ACD-HC trial

High concentrated sodium citrate versus ACD-A for leukapheresis without heparin using centrifugal separation : Open-label, randomized, controlled trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs061250017

Enrollment

Registered

2025-05-15

Start date

2025-05-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PBSC donor

Interventions

Peripheral blood stem cell collection using 5.3% sodium citrate solution (ACD-HC)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: PBSC donor Persons 16 years old and older TBV 4.5 liter or less

Exclusion criteria

Exclusion criteria: Peripheral blood stem cell donors registered with the Japan Marrow Donor Program Persons who are recommended custom priming because whose TBV and Hct values are low

Design outcomes

Primary

Measure	Time frame
procedure time due to apheresis	—

Secondary

Measure	Time frame
total amount of AC product quality assesement collection efficiency platelet reduction rate incidence of adverse effect change in electrolyte values over time incidence rate of clumping and coagulating	—

Contacts

Public ContactKeiko Fujii

Okayama University Hospital

keikofujii@s.okayama-u.ac.jp+81-86-235-7768

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026